Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Gynecologic Oncology
|
February 24, 2009
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial
J E Kurtz, A-C Hardy-Bessard, M Deslandres, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1997
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies
E C Brain, A Mita, P Soulié, et al.
Anticancer Research
|
March 9, 2012
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial
J E Kurtz, G Freyer, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
L Cabel, F Berger, T Bachelot, et al.
British Journal of Cancer
|
February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
I Ray-Coquard, B Weber, J Cretin, et al.
ESMO Open
|
April 12, 2025
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study
S Quesada, A Puszkiel, A Jouinot, et al.
ESMO Open
|
April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial
M Saint-Ghislain, S Chabaud, F Dalenc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
A Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Gynecologic Oncology
|
February 24, 2009
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial
J E Kurtz, A-C Hardy-Bessard, M Deslandres, et al.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1997
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies
E C Brain, A Mita, P Soulié, et al.
Anticancer Research
|
March 9, 2012
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial
J E Kurtz, G Freyer, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
L Cabel, F Berger, T Bachelot, et al.
British Journal of Cancer
|
February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
I Ray-Coquard, B Weber, J Cretin, et al.
ESMO Open
|
April 12, 2025
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study
S Quesada, A Puszkiel, A Jouinot, et al.
ESMO Open
|
April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial
M Saint-Ghislain, S Chabaud, F Dalenc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
A Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Page
of 3